Summary

Asia Pacific Tissue Engineered Skin Substitutes Market is valued approximately at USD 240 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.30% over the forecast period 2024-2032. Tissue-engineered skin substitutes are advanced biomedical devices that are designed to replace damaged skin tissue. When conventional grafts are impractical, they are used to treat severe burns, long-term wounds, and skin disorders. These replacements imitate the layers and functions of normal skin by combining biocompatible materials with live cells from the patient or donors. They are available in three varieties: acellular forms that include proteins and growth factors for healing, live cells for regeneration in cell-based versions, and composite versions that combine the two. These replacements represent a major development in wound care and regenerative medicine, providing less donor site complications, enhanced aesthetics, and quicker healing times. The growing focus on affordability and accessibility of advanced wound care solutions is a key trend for the Asia Pacific Tissue Engineered Skin Substitutes Market during the forecast period of 2024-2032. There is an increasing demand for cost-effective and scalable tissue-engineered skin substitutes that addresses various skin conditions and wounds with the region's diverse healthcare landscape, including emerging economies and underserved regions.

In addition, the expansion of the Tissue Engineered Skin Substitutes Market is predominantly fueled by the ongoing advancement in tissue engineering, biomaterials, and regenerative medicine and the increasing aging population. Also, the rising incidence of chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers is a key factor that is propelling the demand of the tissue-engineered skin substitutes. According to WHO report as of 2023, in India, approximately 77 million individuals aged 18 and above are living with type 2 diabetes, and nearly 25 million are in a prediabetic state, indicating a heightened risk of developing diabetes in the forecast period. Advanced wound care options, such as tissue-engineered skin replacements, are in greater demand as the region's population ages and lifestyle factors become more prevalent causes of chronic health issues. The emergence of developing nations such as China, India, and Japan is poised to drive market expansion in the region. Furthermore, the rapid growth of the medical tourism sector in these countries contributes to the rising demand for tissue-engineered skin substitutes across the region. However, lack of feasible reimbursement policies and inability of reproducing skin appendages is expected to stifle Asia Pacific Tissue Engineered Skin Substitutes Market growth between 2022 and 2032.

The key countries considered for the Asia Pacific Tissue Engineered Skin Substitutes Market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China's Tissue Engineered Skin Substitutes Market holds a dominating position with the highest number of market shares. The market is experiencing rapid growth due to the China faces a burgeoning diabetic population, a major risk factor for chronic wounds such as diabetic foot ulcers. TE skin substitutes offer a promising solution for treating these wounds and preventing complications like amputations. China's tissue-engineered skin substitutes market is propelled by factors like the rising advancements in healthcare technology, government support, rising healthcare expenditure, and increasing awareness among healthcare professionals and patients. Collaborations and partnerships in research and development also contribute to innovation in tissue engineering, driving the adoption of advanced wound care solutions in the country. Whereas, the market in India is expected to grow at the fastest rate over the forecast period.

Major market player included in this report are:
Japan Tissue Engineering Co., Ltd. (JTEC)
CellSeed Inc.
Green Cross Cell Corporation
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10


The detailed segments and sub-segment of the market are explained below:

By Product Type
Natural
Synthetic

By Application
Chronic Wounds
Acute Wounds

By End User
Hospital and Clinic
Ambulatory Surgical Center
Others

By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Asia Pacific Tissue Engineered Skin Substitutes Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Asia Pacific Tissue Engineered Skin Substitutes Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Product Type
2.3.2. By Application
2.3.3. By End User
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Asia Pacific Tissue Engineered Skin Substitutes Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Asia Pacific Tissue Engineered Skin Substitutes Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Asia Pacific Tissue Engineered Skin Substitutes Market Size & Forecasts by Product Type 2022-2032
5.1. Natural
5.2. Synthetic
Chapter 6. Asia Pacific Tissue Engineered Skin Substitutes Market Size & Forecasts by Application 2022-2032
6.1. Chronic Wounds
6.2. Acute Wounds
Chapter 7. Asia Pacific Tissue Engineered Skin Substitutes Market Size & Forecasts by End User 2022-2032
7.1. Hospital and Clinic
7.2. Ambulatory Surgical Center
7.3. Others
Chapter 8. Asia Pacific Tissue Engineered Skin Substitutes Market Size & Forecasts by Country 2022-2032
8.1. China Tissue Engineered Skin Substitutes Market
8.1.1. Product Type breakdown size & forecasts, 2022-2032
8.1.2. Application breakdown size & forecasts, 2022-2032
8.1.3. End User breakdown size & forecasts, 2022-2032
8.2. India Tissue Engineered Skin Substitutes Market
8.3. Japan Tissue Engineered Skin Substitutes Market
8.4. Australia Tissue Engineered Skin Substitutes Market
8.5. South Korea Tissue Engineered Skin Substitutes Market
8.6. Rest of Asia Pacific Tissue Engineered Skin Substitutes Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Japan Tissue Engineering Co., Ltd. (JTEC)
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. CellSeed Inc.
9.3.3. Green Cross Cell Corporation
9.3.4. Company 4
9.3.5. Company 5
9.3.6. Company 6
9.3.7. Company 7
9.3.8. Company 8
9.3.9. Company 9
9.3.10. Company 10
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes